vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Zeo Energy Corp. (ZEO). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $18.6M, roughly 1.1× Zeo Energy Corp.). Zeo Energy Corp. runs the higher net margin — -10.8% vs -177.4%, a 166.6% gap on every dollar of revenue. On growth, Zeo Energy Corp. posted the faster year-over-year revenue change (-0.4% vs -11.5%). Zeo Energy Corp. produced more free cash flow last quarter ($2.3M vs $-23.1M). Over the past eight quarters, Zeo Energy Corp.'s revenue compounded faster (-4.0% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

LAB vs ZEO — Head-to-Head

Bigger by revenue
LAB
LAB
1.1× larger
LAB
$19.6M
$18.6M
ZEO
Growing faster (revenue YoY)
ZEO
ZEO
+11.0% gap
ZEO
-0.4%
-11.5%
LAB
Higher net margin
ZEO
ZEO
166.6% more per $
ZEO
-10.8%
-177.4%
LAB
More free cash flow
ZEO
ZEO
$25.4M more FCF
ZEO
$2.3M
$-23.1M
LAB
Faster 2-yr revenue CAGR
ZEO
ZEO
Annualised
ZEO
-4.0%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
ZEO
ZEO
Revenue
$19.6M
$18.6M
Net Profit
$-34.7M
$-2.0M
Gross Margin
48.5%
Operating Margin
-168.5%
-11.8%
Net Margin
-177.4%
-10.8%
Revenue YoY
-11.5%
-0.4%
Net Profit YoY
-28.8%
-360.9%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
ZEO
ZEO
Q4 25
$18.6M
Q3 25
$19.6M
$23.9M
Q2 25
$21.8M
$18.1M
Q1 25
$40.8M
$8.8M
Q4 24
$18.6M
Q3 24
$22.1M
$19.7M
Q2 24
$22.5M
$14.8M
Q1 24
$45.5M
$20.1M
Net Profit
LAB
LAB
ZEO
ZEO
Q4 25
$-2.0M
Q3 25
$-34.7M
$-3.2M
Q2 25
$-33.5M
$-2.4M
Q1 25
$-26.0M
$-6.4M
Q4 24
$-435.3K
Q3 24
$-26.9M
$-424.3K
Q2 24
$-45.7M
$-277.8K
Q1 24
$-32.2M
$-1.5M
Gross Margin
LAB
LAB
ZEO
ZEO
Q4 25
Q3 25
48.5%
57.9%
Q2 25
48.8%
59.8%
Q1 25
48.4%
99.3%
Q4 24
Q3 24
54.9%
50.2%
Q2 24
46.1%
52.3%
Q1 24
53.1%
Operating Margin
LAB
LAB
ZEO
ZEO
Q4 25
-11.8%
Q3 25
-168.5%
-8.3%
Q2 25
-118.1%
-15.8%
Q1 25
-80.8%
-153.8%
Q4 24
-6.0%
Q3 24
-120.9%
-15.2%
Q2 24
-134.5%
-18.0%
Q1 24
-132.2%
-20.1%
Net Margin
LAB
LAB
ZEO
ZEO
Q4 25
-10.8%
Q3 25
-177.4%
-13.5%
Q2 25
-153.7%
-13.3%
Q1 25
-63.8%
-72.4%
Q4 24
-2.3%
Q3 24
-122.0%
-2.2%
Q2 24
-203.3%
-1.9%
Q1 24
-70.6%
-7.6%
EPS (diluted)
LAB
LAB
ZEO
ZEO
Q4 25
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
$-0.48
Q4 24
$1.11
Q3 24
$-0.07
$-0.08
Q2 24
$-0.12
$0.03
Q1 24
$-0.27
$-1.54

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
ZEO
ZEO
Cash + ST InvestmentsLiquidity on hand
$129.4M
$6.1M
Total DebtLower is stronger
$79.1K
Stockholders' EquityBook value
$399.7M
$5.3M
Total Assets
$539.6M
$56.9M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
ZEO
ZEO
Q4 25
$6.1M
Q3 25
$129.4M
$3.9M
Q2 25
$158.6M
$68.7K
Q1 25
$150.9M
$2.9M
Q4 24
$5.6M
Q3 24
$210.6M
$4.3M
Q2 24
$269.8M
$5.3M
Q1 24
$287.1M
Total Debt
LAB
LAB
ZEO
ZEO
Q4 25
$79.1K
Q3 25
$84.6K
Q2 25
$642.8K
Q1 25
$715.4K
Q4 24
$787.7K
Q3 24
$55.2M
$858.6K
Q2 24
$55.1M
$1.6M
Q1 24
$55.0M
$748.8K
Stockholders' Equity
LAB
LAB
ZEO
ZEO
Q4 25
$5.3M
Q3 25
$399.7M
$-1.7M
Q2 25
$424.5M
$-59.4M
Q1 25
$454.6M
$-23.1M
Q4 24
$-88.9M
Q3 24
$489.3M
$-39.3M
Q2 24
$510.3M
$-53.0M
Q1 24
$577.3M
$-173.0M
Total Assets
LAB
LAB
ZEO
ZEO
Q4 25
$56.9M
Q3 25
$539.6M
$58.5M
Q2 25
$557.0M
$46.2M
Q1 25
$579.6M
$47.4M
Q4 24
$61.0M
Q3 24
$681.5M
$47.1M
Q2 24
$708.7M
$49.1M
Q1 24
$777.7M
$50.1M
Debt / Equity
LAB
LAB
ZEO
ZEO
Q4 25
0.01×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
ZEO
ZEO
Operating Cash FlowLast quarter
$-22.2M
$2.4M
Free Cash FlowOCF − Capex
$-23.1M
$2.3M
FCF MarginFCF / Revenue
-118.1%
12.2%
Capex IntensityCapex / Revenue
4.5%
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$-9.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
ZEO
ZEO
Q4 25
$2.4M
Q3 25
$-22.2M
$-6.6M
Q2 25
$-20.7M
$-2.3M
Q1 25
$-30.3M
$-2.3M
Q4 24
$3.5M
Q3 24
$-27.9M
$162.2K
Q2 24
$-39.0M
$-2.2M
Q1 24
$-62.5M
$-10.2M
Free Cash Flow
LAB
LAB
ZEO
ZEO
Q4 25
$2.3M
Q3 25
$-23.1M
$-6.8M
Q2 25
$-22.6M
$-2.7M
Q1 25
$-35.3M
$-2.6M
Q4 24
$3.4M
Q3 24
$-30.1M
$116.5K
Q2 24
$-41.0M
$-2.3M
Q1 24
$-63.3M
$-10.4M
FCF Margin
LAB
LAB
ZEO
ZEO
Q4 25
12.2%
Q3 25
-118.1%
-28.6%
Q2 25
-103.6%
-15.0%
Q1 25
-86.6%
-30.0%
Q4 24
18.2%
Q3 24
-136.4%
0.6%
Q2 24
-182.2%
-15.6%
Q1 24
-138.9%
-51.5%
Capex Intensity
LAB
LAB
ZEO
ZEO
Q4 25
0.9%
Q3 25
4.5%
1.0%
Q2 25
8.7%
2.4%
Q1 25
12.4%
4.2%
Q4 24
0.5%
Q3 24
10.2%
0.2%
Q2 24
8.6%
0.7%
Q1 24
1.7%
1.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

ZEO
ZEO

Nonrelated Party$18.1M98%
Related Party$432.1K2%

Related Comparisons